Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy

被引:25
作者
Wi, Chung-Il [1 ]
Loo, Nicole M. [6 ]
Larson, Joseph J. [2 ]
Moynihan, Timothy J. [3 ]
Madde, Nageswar R. [4 ]
Grendahl, Darryl C. [5 ]
Alberts, Steven R. [3 ]
Kim, W. Ray [1 ,7 ]
机构
[1] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN USA
[2] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Rochester, MN USA
[3] Mayo Clin, Coll Med, Div Med Oncol, Rochester, MN USA
[4] Mayo Clin, Coll Med, Div Informat Technol, Rochester, MN USA
[5] Mayo Clin, Coll Med, Div Pharm Serv, Rochester, MN USA
[6] Yale Univ, Sect Digest Dis, New Haven, CT USA
[7] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94304 USA
基金
美国国家卫生研究院;
关键词
Universal Screening; Abnormal Liver Enzyme; Preemptive Antiviral; Risk Factor; PREEMPTIVE LAMIVUDINE; COST-EFFECTIVENESS; REACTIVATION; INFECTION; LYMPHOMA; THERAPY;
D O I
10.1016/j.cgh.2014.10.032
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Chemotherapy of patients with inactive hepatitis B virus (HBV) infection can lead to viral reactivation and hepatitis flares. We investigated the proportion of patients screened for HBV infection before chemotherapy over time and the outcomes of screened patients. METHODS: In a retrospective study, we collected data from a pharmacy database on patients who underwent cytotoxic chemotherapy for solid or hematologic malignancies at the Mayo Clinic in Rochester, Minnesota, from January 1, 2006, through September 30, 2011. Laboratory data were collected from electronic medical records. Screening was identified based on tests for hepatitis B surface antigen, for any reason at any time before chemotherapy. RESULTS: Of 8005 patients undergoing chemotherapy, 1279 (16%) were screened for HBV infection before chemotherapy, including 668 of 1805 patients with hematologic malignancies (37%). The proportion of patients screened for HBV increased from 14.3% in 2006 to 2008 to 17.7% in 2009 to 2011 (P < .01). This trend was attributed mostly to an increase in the proportion of patients with hematologic malignancies, from 32.7% in 2006 to 2008 to 40.6% in 2009 to 2011 (P < .01). Of 13 patients who tested positive for HBV, 5 did not receive prophylactic antiviral therapy; HBV infection was reactivated in 2 of these patients. None of the 8 patients who received an antiviral agent before chemotherapy experienced HBV reactivation. Of 58 unscreened patients who had increases in their alanine aminotransferase level (>300 U/L), only 1 patient appeared to have an undiagnosed HBV infection. CONCLUSIONS: Only a small percentage of patients receiving chemotherapy are screened for HBV infection. However, a larger proportion of patients was screened during 2009 to 2011 than during 2006 to 2008, especially patients with hematologic malignancies. Strategies are needed to ensure that patients receiving chemotherapy are protected from the consequences of undiagnosed HBV infection.
引用
收藏
页码:970 / 975
页数:6
相关论文
共 14 条
[1]   American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases [J].
Artz, Andrew S. ;
Somerfield, Mark R. ;
Feld, Jordan J. ;
Giusti, Andrew F. ;
Kramer, Barnett S. ;
Sabichi, Anita L. ;
Zon, Robin T. ;
Wong, Sandra L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3199-3202
[2]   Current Hepatitis B Screening Practices and Clinical Experience of Reactivation in Patients Undergoing Chemotherapy for Solid Tumors: A Nationwide Survey of Medical Oncologists [J].
Day, Fiona L. ;
Link, Emma ;
Thursky, Karin ;
Rischin, Danny .
JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (03) :141-147
[3]   Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors [J].
Day, Fiona L. ;
Karnon, Jonathan ;
Rischin, Danny .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3270-3277
[4]   A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial [J].
Hsu, Chiun ;
Hsiung, Chao A. ;
Su, Lh-Jen ;
Hwang, Wei-Shou ;
Wang, Ming-Chung ;
Lin, Sheng-Fung ;
Lin, Tseng-Hsi ;
Hsiao, Hui-Hua ;
Young, Ji-Hsiung ;
Chang, Ming-Chih ;
Liao, Yu-Min ;
Li, Chi-Cheng ;
Wu, Hung-Bo ;
Tien, Hwei-Fang ;
Chao, Tsu-Yi ;
Hu, Tsang-Wu ;
Cheng, Ann-Lii ;
Chen, Pei-Jer .
HEPATOLOGY, 2008, 47 (03) :844-853
[5]   Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy [J].
Hwang, Jessica P. ;
Fisch, Michael J. ;
Zhang, Hong ;
Kallen, Michael A. ;
Routbort, Mark J. ;
Lal, Lincy S. ;
Vierling, John M. ;
Suarez-Almazor, Maria E. .
JOURNAL OF ONCOLOGY PRACTICE, 2012, 8 (04) :E32-E39
[6]  
Hwang JP, 2013, AASLD EM TRENDS C 20
[7]   A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization [J].
Jang, JW ;
Choi, JY ;
Bae, SH ;
Yoon, SK ;
Chang, UI ;
Kim, CW ;
Cho, SH ;
Han, JY ;
Lee, YS .
HEPATOLOGY, 2006, 43 (02) :233-240
[8]   Oncologists and Hepatitis B: A Survey to Determine Current Level of Awareness and Practice of Antiviral Prophylaxis to Prevent Reactivation [J].
Khokhar, Omar S. ;
Farhadi, Arash ;
McGrail, Lisa ;
Lewis, James H. .
CHEMOTHERAPY, 2009, 55 (02) :69-75
[9]   Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy [J].
Lau, GKK ;
Yiu, HHY ;
Fong, DYT ;
Cheng, HC ;
Au, WY ;
Lai, LSF ;
Cheung, M ;
Zhang, HY ;
Lie, A ;
Ngan, R ;
Liang, R .
GASTROENTEROLOGY, 2003, 125 (06) :1742-1749
[10]   Chronic Hepatitis B: Update 2009 [J].
Lok, Anna S. F. ;
McMahon, Brian J. .
HEPATOLOGY, 2009, 50 (03) :661-662